VNX001

DRUG2 trials

Sponsors

Vaneltix Pharma, Inc.

Conditions

Bladder Pain SyndromeInterstitial Cystitis

Phase 2

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

RecruitingNCT05737121

Vaneltix Pharma, Inc.Bladder Pain Syndrome, Interstitial Cystitis

Start: 2023-05-22End: 2026-06-01Target: 120Updated: 2026-01-22

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

RecruitingNCT06394830

Vaneltix Pharma, Inc.Bladder Pain Syndrome, Interstitial Cystitis

Start: 2024-12-13End: 2026-06-01Target: 50Updated: 2026-01-22